Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000011753 | SCV005886877 | likely pathogenic | Ornithine carbamoyltransferase deficiency | 2025-01-31 | criteria provided, single submitter | clinical testing | Variant summary: OTC c.236G>A (p.Gly79Glu) results in a non-conservative amino acid change located in the Aspartate/ornithine carbamoyltransferase, carbamoyl-P binding domian (IPR006132) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 182630 control chromosomes (gnomAD). c.236G>A has been reported in the literature in individuals affected with Ornithine Transcarbamylase Deficiency (Tuchman_1992, McCullough_2000). At least one publication reports experimental evidence evaluating an impact on protein function and this variant affected OTC protein function (Tuchman_2002). The following publications have been ascertained in the context of this evaluation (PMID: 36303552, 37146589, 28324312, 10946359, 11793468, 1480464, 16786505). ClinVar contains an entry for this variant (Variation ID: 11006). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
OMIM | RCV000011753 | SCV000031985 | pathogenic | Ornithine carbamoyltransferase deficiency | 2002-02-01 | no assertion criteria provided | literature only | |
Gen |
RCV000083369 | SCV000115455 | pathogenic | not provided | no assertion criteria provided | not provided | Converted during submission to Pathogenic. |